Abstract: Cysteinyl-leukotrienes (Cys-LTs) and LTB4 are potent proinflammatory mediators de- rived from arachidonic acid through the 5-lipoxy- genase (5-LO) pathway, which exerts important pharmacological effects through their interaction with specific receptors: Cys-LT receptors (CysLT1 and CysLT2) and LTB4 receptors (BLT1 and BLT2). Published evidence justifies a broader role for LT receptor antagonists (LTRAs), in particular, montelukast, in the treatment of bronchial asthma, allergic rhinitis, and recently, in cardiocerebrovas- cular disease. The actions of Cys-LTs on the car- diovascular (CV) system are well-documented and include a broad array of activities with promising therapeutic targets in animal models exploring the use of selective 5-LO (or 5-LO-activating protein) inhibitors or dual LO-cycloxygenase-blocking agents in experimentally induced acute myocardial infarction. The picture that emerges from studies with LTRAs is more controversial at the moment, and some findings suggest a role for Cys-LTs in the extension of ischemic damage and in cardiac dys- function during reperfusion; others do not. The aim of this short review is to summarize the state of present research about LT modifier treatment in CV disease.
File in questo prodotto:
Non ci sono file associati a questo prodotto.